SEC 13F Intelligence

Decheng Capital Management III (Cayman), LLC / PACB

Decheng Capital Management III (Cayman), LLC’s Pacific Biosciences Calif In Position

Does Decheng Capital Management III (Cayman), LLC own Pacific Biosciences Calif In (PACB)? Yes — 1.46M shares worth $12M (+4.08% of its 13F portfolio) as of Q4 2023.

Position Value
$12M
Q4 2023
Shares
1.46M
% of Portfolio
+4.08%
Quarters Held
8
currently held

Position History PACB

Reported value by quarter
Q1 ’22: $13MQ1 ’22Q2 ’22: $6MQ2 ’22Q3 ’22: $9MQ3 ’22Q4 ’22: $12MQ4 ’22Q1 ’23: $17MQ1 ’23Q2 ’23: $19MQ2 ’23Q3 ’23: $12MQ3 ’23Q4 ’23: $12MQ4 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q4 20231.46M$12M+4.08%
Q3 20231.46M$12M+3.91%
Q2 20231.46M$19M+6.11%
Q1 20231.46M$17M+6.84%
Q4 20221.46M$12M+4.48%
Q3 20221.46M$9M+3.08%
Q2 20221.46M$6M+2.45%
Q1 20221.46M$13M+4.08%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Decheng Capital Management III (Cayman), LLC’s full portfolio or all institutional holders of PACB.